After Catalent disclosed plans to lay off hundreds of workers in the second half of last year, it appears the company's ...

Arcutis Biotherapeutics and Kowa Pharmaceuticals are cutting ties on their U.S. marketing partnership around Arcutis’ Zoryve ...

With the FDA tightening its guidance around the production of nonbacterial beta-lactam drugs, Swedish CDMO Recipharm is ...

With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug conjugates. | With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug ...

The new chairman of the CDC's Advisory Committee on Immunization Practices, Kirk Milhoan, M.D., Ph.D., recently took to the ...

Plotting a challenge to Regeneron’s blockbuster Eylea, Ocular Therapeutix has hired “a key architect” of its rival’s launch ...

In 2025's third quarter, multiple large vaccine developers, including Pfizer and GSK, saw vaccine sales tick up globally ...

With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...

GLP-1 giant Eli Lilly has once again taken to the medium of short film to deliver an important message about obesity. | GLP-1 ...

Amid a viral social media trend glorifying the halcyon days of 2016, Novo Nordisk has gone back an extra decade to find ...

As Sandoz looks to address the “biosimilar void” created by the scores of lucrative drugs going off patent in the next decade ...

While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026. | While the threat of U.S. import tariffs ...